After all, this is the first report to demonstrate the suppression of fibrosis‐related genes in kidneys by a STAT3 dimerization inhibitor, and to suggest that STX‐0119 may be a new candidate for treating CKD via the slowing of kidney fibrosis. Here, STAT3 is linked to chronic kidney disease.